Table 5.
Prognostic value of baseline lipid concentrations on risk of end point occurrence obtained by recurrent events time-to-event analysis
| End point | HDL Cholesterol | ApoA1 | ApoA2 | ApoC3 | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI)a | P Valueb | HR (95% CI)a | P Valueb | HR (95% CI)a | P Valueb | HR (95% CI)a | P Valueb | |
| Combined vascular end pointc | ||||||||
| Q2 | 1.02 (0.80 to 1.31) | 0.85 | 1.14 (0.90 to 1.44) | 0.29 | 0.78 (0.61 to 1.00) | 0.05 | 0.94 (0.74 to 1.19) | 0.60 |
| Q3 | 0.96 (0.75 to 1.23) | 0.75 | 0.93 (0.72 to 1.20) | 0.58 | 0.94 (0.74 to 1.20) | 0.61 | 0.98 (0.77 to 1.24) | 0.87 |
| Q4 | 1.06 (0.83 to 1.35) | 0.65 | 0.93 (0.73 to 1.19) | 0.57 | 0.74 (0.58 to 0.96) | 0.02 | 0.93 (0.73 to 1.19) | 0.58 |
| Overalld | 0.88 | 0.33 | 0.05 | 0.93 | ||||
| Cardiac death | ||||||||
| Q2 | 0.99 (0.71 to 1.39) | 0.97 | 1.16 (0.84 to 1.62) | 0.37 | 0.76 (0.54 to 1.07) | 0.12 | 0.95 (0.67 to 1.35) | 0.78 |
| Q3 | 0.82 (0.58 to 1.18) | 0.29 | 0.96 (0.67 to 1.31) | 0.80 | 0.84 (0.59 to 1.18) | 0.31 | 1.21 (0.87 to 1.70) | 0.26 |
| Q4 | 1.03 (0.74 to 1.43) | 0.88 | 0.92 (0.65 to 1.31) | 0.65 | 0.64 (0.45 to 0.93) | 0.02 | 0.85 (0.59 to 1.23) | 0.39 |
| Overall | 0.62 | 0.54 | 0.11 | 0.21 | ||||
| Sudden cardiac death | ||||||||
| Q2 | 0.92 (0.59 to 1.43) | 0.71 | 0.86 (0.55 to 1.34) | 0.50 | 0.60 (0.39 to 0.94) | 0.02 | 0.95 (0.60 to 1.50) | 0.82 |
| Q3 | 0.78 (0.49 to 1.25) | 0.30 | 0.99 (0.63 to 1.55) | 0.98 | 0.69 (0.44 to 1.07) | 0.10 | 1.23 (0.79 to 1.90) | 0.36 |
| Q4 | 1.13 (0.74 to 1.73) | 0.56 | 0.95 (0.61 to 1.47) | 0.82 | 0.61 (0.39 to 0.97) | 0.04 | 0.84 (0.52 to 1.35) | 0.46 |
| Overall | 0.43 | 0.91 | 0.09 | 0.36 | ||||
| Nonfatal MI | ||||||||
| Q2 | 1.16 (0.74 to 1.82) | 0.51 | 1.13 (0.73 to 1.75) | 0.58 | 0.82 (0.51 to 1.32) | 0.42 | 0.92 (0.57 to 1.47) | 0.72 |
| Q3 | 1.17 (0.75 to 1.83) | 0.49 | 1.01 (0.64 to 1.60) | 0.96 | 1.12 (0.71 to 1.76) | 0.64 | 1.01 (0.64 to 1.60) | 0.97 |
| Q4 | 1.11 (0.71 to 1.74) | 0.65 | 0.98 (0.63 to 1.52) | 0.91 | 0.84 (0.53 to 1.35) | 0.48 | 1.25 (0.81 to 1.93) | 0.32 |
| Overall | 0.90 | 0.91 | 0.42 | 0.54 | ||||
| All cardiac events | ||||||||
| Q2 | 1.21 (0.96 to 1.52) | 0.10 | 1.36 (1.09 to 1.71) | 0.01 | 0.83 (0.65 to 1.05) | 0.13 | 0.86 (0.68 to 1.10) | 0.24 |
| Q3 | 1.02 (0.80 to 1.30) | 0.89 | 1.07 (0.84 to 1.37) | 0.59 | 0.94 (0.74 to 1.19) | 0.61 | 1.06 (0.84 to 1.34) | 0.61 |
| Q4 | 1.10 (0.87 to 1.39) | 0.42 | 0.98 (0.77 to 1.25) | 0.88 | 0.73 (0.57 to 0.94) | 0.02 | 0.94 (0.74 to 1.19) | 0.60 |
| Overall | 0.33 | 0.01 | 0.01 | 0.34 | ||||
| All cerebrovascular events | ||||||||
| Q2 | 0.98 (0.63 to 1.52) | 0.91 | 0.96 (0.62 to 1.47) | 0.84 | 0.99 (0.64 to 1.53) | 0.95 | 0.86 (0.57 to 1.29) | 0.46 |
| Q3 | 1.05 (0.68 to 1.62) | 0.82 | 0.79 (0.50 to 1.24) | 0.31 | 0.83 (0.52 to 1.32) | 0.43 | 0.65 (0.42 to 1.07) | 0.05 |
| Q4 | 1.06 (0.69 to 1.62) | 0.80 | 1.01 (0.67 to 1.53) | 0.96 | 0.91 (0.58 to 1.42) | 0.68 | 0.76 (0.49 to 1.17) | 0.22 |
| Overall | 0.98 | 0.68 | 0.84 | 0.27 | ||||
| Death from all causes | ||||||||
| Q2 | 0.93 (0.74 to 1.16) | 0.50 | 0.97 (0.77 to 1.21) | 0.78 | 0.77 (0.62 to 0.96) | 0.02 | 0.84 (0.67 to 1.05) | 0.13 |
| Q3 | 0.79 (0.63 to 0.99) | 0.04 | 0.95 (0.76 to 1.20) | 0.68 | 0.75 (0.59 to 0.94) | 0.01 | 0.93 (0.74 to 1.16) | 0.50 |
| Q4 | 0.94 (0.76 to 1.17) | 0.60 | 0.89(0.71 to 1.20) | 0.32 | 0.63 (0.49 to 0.80) | <0.001 | 0.78 (0.61 to 0.98) | 0.04 |
| Overall | 0.23 | 0.80 | 0.002 | 0.15 | ||||
HR, hazard ratio; 95% CI, 95% confidence interval; Q, quartile; MI, myocardial infarction.
a
HR calculated with multivariate Andersen–Gill model; group of patients within the first quarter of the distribution used as the reference group; atorvastatin and placebo group pooled; multiple events considered.
b
P value of the Wald test statistic.
c
Combined vascular end point consisting of MI, cardiac death, and stroke.
d
P value of the multivariate Wald test statistic investigating whether there was any difference between any two quartiles.